{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-117172","form_type":"8-K","ticker":"HYPD","cik":"0001682639","company_name":"HYPERION DEFI, INC.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.702122+00:00","generated_at":"2026-06-21T23:09:46.619237+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Eyenovia reports Q3 2022 net loss of $7.3M; MicroLine VISION-2 Phase 3 trial meets primary endpoint","bullets":["Net loss of $7.3M ($0.21 per share) vs $5.6M loss in Q3 2021; cash $25.3M (incl. $7.9M restricted) as of Sep 30, 2022.","VISION-2 trial achieved primary endpoint: statistically significant ≥15-letter DCNVA improvement at 2 hours; FDA meeting planned.","Michael Rowe appointed CEO (former COO) and to Board of Directors; manufacturing facility in Redwood City, CA now operational.","Arctic Vision Phase 3 trial of MicroLine in China enrolling patients; expects completion in late 2023.","Collaboration with Bausch+Lomb and Optejet out-licensing progress noted; company evaluating additional partnerships."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-117172","json":"https://secwatch.observer/filing/0001104659-22-117172.json","markdown":"https://secwatch.observer/filing/0001104659-22-117172.md","text":"https://secwatch.observer/filing/0001104659-22-117172.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1682639/000110465922117172/0001104659-22-117172-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1682639/000110465922117172/tm2230140d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T23:09:46.619237+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4c9749d4484c5058111a3d17a780ff96cb6e4c92","claim":"HYPERION DEFI, INC. reported third quarter ended September 30, 2022 results: net income net loss was approximately $(7.3) million, or $(0.21) per share, EPS $(0.21) per share.","evidence_excerpt":"Eyenovia, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1682639/000110465922117172/0001104659-22-117172-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Net income","value":"net loss was approximately $(7.3) million, or $(0.21) per share"},{"label":"EPS","value":"$(0.21) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}